ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors
Phase 1 Completed
28 enrolled
IPATHER
Phase 1 Completed
17 enrolled
Pulsed Electromagnetic Fields (PEMFs) - A Highly Selective Breast CAncer Treatment pLatform (PASCAL)
Phase 1 Completed
14 enrolled
Adjuvant
Phase 1 Completed
15 enrolled 8 charts
REDEX
Phase 1 Completed
46 enrolled
A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer
Phase 1 Completed
32 enrolled 23 charts
Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors
Phase 1 Completed
21 enrolled
A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors
Phase 1 Completed
93 enrolled
Evaluating the Performance of AI in Evaluating Breast MRI Performed With Dose Reduction
Phase 1 Completed
20 enrolled
Neoadjuvant Chemotherapy With WH002 in Women With HER2-negative Breast Cancer
Phase 1 Completed
40 enrolled
A Trial of Itraconazole Effect on HRS-8080 Pharmacokinetics in Healthy Participants
Phase 1 Completed
16 enrolled
A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors
Phase 1 Completed
40 enrolled
Endoxifen in Adults With Hormone Receptor Positive Solid Tumors
Phase 1 Completed
40 enrolled
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of RP903
Phase 1 Completed
69 enrolled
CLINICAL RESEARCH PROTOCOL [A Phase I, Single-arm, Open-label, Dose-escalation Clinical Study to Evaluate the Safety and Tolerability of Orialpha (BD-C) in Healthy Adult Volunteers]
Phase 1 Completed
15 enrolled
A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors
Phase 1 Completed
168 enrolled
A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy
Phase 1 Completed
31 enrolled 12 charts
Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases
Phase 1 Completed
14 enrolled
Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)
Phase 1 Completed
16 enrolled 10 charts
Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers
Phase 1 Completed
53 enrolled
EMBER-2
Phase 1 Completed
87 enrolled 13 charts
TACTIVE-E
Phase 1 Completed
32 enrolled
Study to Determine Absorption, Metabolism, and Excretion of [14C]-SAR439859, and to Assess Absolute Oral Bioavailability of Amcenestrant (SAR439859), in Healthy Post-menopausal Women
Phase 1 Completed
6 enrolled
Phase 1 Study of FS-1502 in Patients With HER2 Expressed Advanced Solid Tumors and Breast Cancer.
Phase 1 Completed
161 enrolled
A Study to Investigate the Pharmacokinetics of Midazolam After Repeated Doses of Camizestrant (AZD9833) and to Investigate the Pharmacokinetics of Camizestrant When Administered Alone and in Combination With Carbamazepine in Healthy Post-Menopausal Female Participants
Phase 1 Completed
40 enrolled
Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer
Phase 1 Completed
23 enrolled 10 charts
A Phase 1 Study of AZD9833 in Japanese Women With ER Positive, HER2 Negative Advanced Breast Cancer
Phase 1 Completed
10 enrolled
Safety Study of 3D Printing Personalized Biodegradable Implant for Breast Reconstruction
Phase 1 Completed
30 enrolled
CNSI-Fe(II)
Phase 1 Completed
19 enrolled 47 charts
A Study to Compare PK, Immunogenicity and Safety of Trastuzumab of Incepta Pharmaceuticals Ltd With Trastuzumab (Roche)
Phase 1 Completed
80 enrolled
Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies
Phase 1 Completed
23 enrolled
Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules
Phase 1 Completed
285 enrolled
B-PRECISE-01
Phase 1 Completed
62 enrolled 18 charts
This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer
Phase 1 Completed
133 enrolled 26 charts
Doxil/Caelyx BE Study
Phase 1 Completed
36 enrolled
T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer
Phase 1 Completed
20 enrolled
A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China
Phase 1 Completed
17 enrolled
Study of the Imaging Agent 18F-Var3 in Patients With Breast Cancer
Phase 1 Completed
6 enrolled
Study of the Combination of Vorinostat and Radiation Therapy for the Treatment of Patients With Brain Metastases
Phase 1 Completed
17 enrolled 8 charts
NAC
Phase 1 Completed
13 enrolled
Molecular Imaging of Gastrin Releasing Peptide Receptors Using Labeled Technetium-99m DB8
Phase 1 Completed
10 enrolled
Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer
Phase 1 Completed
66 enrolled
Feasibility of Implementing Acupuncture Into Federally Qualified Health Center Among Breast Cancer Survivors
Phase 1 Completed
62 enrolled
Open Multi-cohort Study of the First Phase of Safety of a Drug Based on Double Recombinant Vaccinia Virus VV-GMCSF-Lact
Phase 1 Completed
34 enrolled
Oral STAT3 Inhibitor, TTI-101, in Patients with Advanced Cancers
Phase 1 Completed
64 enrolled
A Clinical Study to Determine the Pharmacokinetics of Oraxol in Breast Cancer Patients
Phase 1 Completed
28 enrolled 20 charts
Safety Study of MGAH22 in HER2-positive Carcinomas
Phase 1 Completed
66 enrolled
Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.
Phase 1 Completed
13 enrolled 11 charts
Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With HerceptinĀ® in Patients With HER2-positive Advanced Breast Cancer.
Phase 1 Completed
18 enrolled 14 charts
WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor
Phase 1 Completed
19 enrolled